Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM)

Giulia Pasello, Giuseppe Marulli, Valentina Polo, Cristiano Breda, Laura Bonanno, Lucio Loreggian, Federico Rea, Adolfo Favaretto

Research output: Contribution to journalArticle

Abstract

Aim: The objective of this study was the retrospective evaluation of tolerability and activity of pemetrexed with carboplatin (AC) or cisplatin (AP) as neoadjuvant chemotherapy in a consecutive series of patients with malignant pleural mesothelioma (MPM). Patients and Methods: Patients with operable MPM received three cycles of AC or AP followed by surgery and radiotherapy. Results: Since 2005, 51 patients have been treated with AC (27) and AP (24). We observed higher incidence of grade 3 anaemia, cumulative grade 2-3 asthenia and worsening of performance status in the AP group. Response to AC and AP were; complete: 4% vs. 0%, partial: 18% vs. 17%, stable disease: 74% vs. 79%, progressive disease: 4%; the resection rate was 81% vs. 79%. Conclusion: AC and AP are active and feasible neoadjuvant regimens. Progression-free survival, response, disease control and resection rate were similar in the two treatment groups. The lower tolerability to AP treatment could impair the clinical condition of patients undergoing surgery.

Original languageEnglish
Pages (from-to)5393-5399
Number of pages7
JournalAnticancer Research
Volume32
Issue number12
Publication statusPublished - Dec 2012

Keywords

  • Carboplatin
  • Cisplatin
  • Mesothelioma
  • Neoadjuvant
  • Pemetrexed

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM)'. Together they form a unique fingerprint.

  • Cite this